Previous 10 | Next 10 |
Q BioMed Expands Strontium89 Reach Through Agreement with UroGPO, the Largest Group Purchasing Organization for Independent Urology Clinics in the US PR Newswire NEW YORK , Feb. 1, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage ...
The FDA has designated Orphan Drug status to Q BioMed's (QBIO) Uttroside-B, a small molecule chemotherapeutic for the treatment of hepatocellular carcinoma, the most common form of liver cancer.In preclinical studies, Uttroside-B was up to 10-times more potent against hepatocel...
Q BioMed's Uttroside-B Receives U.S. FDA Orphan Drug Designation in the Treatment of Liver Cancer PR Newswire NEW YORK , Jan. 27, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), announced today that the U.S. Food and Drug Administration's Office of...
Q BioMed's Uttroside-B Receives Additional Patent Coverage in Canada and Japan PR Newswire NEW YORK , Jan. 26, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), announces that it has received additional notices of patent allowances from both Canada...
Strontium89 Now Reimbursed in Hospital and Outpatient Settings for Metastatic Bone Pain Treatment Strontium89 Now Reimbursed in All Treatment Settings PR Newswire NEW YORK , Jan. 7, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial s...
Commercial stage biotech company Q BioMed Inc. (QBIO) said it expects revenue from its Metastatic Bone Cancer treatment Strontium89 to ramp next year adding that it expects the treatment to be fully reimbursed by Medicare in the hospital out-patient setting. Q BioMed ...
Q BioMed Updates Shareholders at Year End Company Expects Several Milestones as Momentum Builds for 2021 PR Newswire NEW YORK , Dec. 29, 2020 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO ), a commercial stage biotech company, today issued a ...
Q BioMed Technology Partner Mannin Research Inc. Announced as Member of Canadian National COVID-19 Consortium Group Secures $5.1M to Expand Platform for COVID Research PR Newswire NEW YORK , Dec. 21, 2020 /PRNewswire/ -- Q BioMed, Inc. (OTCQB: QBIO) ...
Q BioMed's Strontium89 Advertisement "Unfinished Business" Selected for Prestigious Ads of the World's Best Creative Campaigns Recognition supports Q BioMed's efforts in making Strontium89 available to patients who need relief from metastatic bone cancer pain PR Newswire ...
Q BioMed's Uttroside-B Receives U.S. Patent in Treatment of Liver Cancer PR Newswire NEW YORK, Nov. 16, 2020 NEW YORK , Nov. 16, 2020 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO ), announces that it has received a patent from the U.S. Paten...
News, Short Squeeze, Breakout and More Instantly...
Veradigm Inc. (MDRX) is expected to report $0.17 for Q3 2023 Aperam SA New York Shares (APEMY) is expected to report for Q3 2023 HTG Molecular Diagnostics Inc. (HTGMQ) is expected to report for Q3 2023 Enel Spa ADR (ENLAY) is expected to report for Q3 2023 Firm Capital Property Tr...
Impac Mortgage Holdings, Inc. (IMPM) is expected to report for quarter end 2023-09-30 Westbury Bancorp Inc (WBBW) is expected to report for quarter end 2023-09-30 Aldeyra Therapeutics Inc. (ALDX) is expected to report $-0.24 for Q3 2023 Zalando SE ADR (ZLNDY) is expected to report for...
thyssenkrupp AG (TYEKF) is expected to report for Q4 2023 Azul S.A. American Depositary Shares (each representing three preferred shares) (AZUL) is expected to report $-0.38 for Q3 2023 Bath & Body Works Inc. (BBWI) is expected to report $0.36 for Q3 2024 Johnson Controls Internat...